United Therapeutics Corporation (UTHR)Healthcare | Drug Manufacturers - Specialty & Generic | Silver Spring, United States | NasdaqGS
515.46 USD
-12.45
(-2.358%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 515.46 |
Hot Take ↕ | Aug. 22, 2026, 2:23 a.m. EDT
United Therapeutics presents a classic value-versus-growth dilemma. While the company boasts a fortress balance sheet with massive cash reserves and industry-leading profit margins, the top line is contracting, which caps the long-term investment thesis. The recent insider selling by the CEO adds a layer of caution for the near term, coinciding with the stock trading below its key moving averages. However, the analyst consensus sees significant upside potential, and the statistical forecast suggests a modest dip ahead. For investors, this is a hold for income seekers who can tolerate no dividends, or a speculative play on a turnaround in revenue growth, but it lacks the explosive momentum required for a high-conviction short-term trade. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.016251 |
| AutoETS | 0.020929 |
| MSTL | 0.020964 |
| AutoARIMA | 0.023066 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 59% |
| H-stat | 14.52 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.803 |
| Excess Kurtosis | -0.48 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 72.852 |
| Market Cap | 22,108,436,480 |
| Trailing P/E | 18.91 |
| Forward P/E | 17.16 |
| Beta | 0.56 |
| Profit Margins | 41.56% |
| Website | https://www.unither.com |
As of Aug. 22, 2026, 2:23 a.m. EDT: Speculators are positioning for a range-bound battle near current levels. Heavy put open interest sits just below the current price, suggesting a defensive floor, while call open interest clusters higher at 580 and 600, indicating upside targets. Deep out-of-the-money strikes show elevated implied volatility, hinting at expectations for significant moves in either direction. The mix suggests a wait-and-see approach rather than a strong directional bet.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.30409324 |
| Address1 | 1,000 Spring Street |
| All Time High | 609.35 |
| All Time Low | 4.275 |
| Ask | 528.2 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 443,090 |
| Average Daily Volume3 Month | 503,933 |
| Average Volume | 503,933 |
| Average Volume10Days | 443,090 |
| Beta | 0.564 |
| Bid | 516.47 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 149.971 |
| City | Silver Spring |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 515.46 |
| Current Ratio | 5.732 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 530.5 |
| Day Low | 513.72 |
| Display Name | United Therapeutics |
| Earnings Call Timestamp End | 1,785,934,800 |
| Earnings Call Timestamp Start | 1,785,934,800 |
| Earnings Growth | 0.134 |
| Earnings Quarterly Growth | 0.076 |
| Earnings Timestamp | 1,785,933,000 |
| Earnings Timestamp End | 1,793,190,600 |
| Earnings Timestamp Start | 1,793,190,600 |
| Ebitda | 1,496,199,936 |
| Ebitda Margins | 0.47431 |
| Enterprise To Ebitda | 12.997 |
| Enterprise To Revenue | 6.165 |
| Enterprise Value | 19,446,136,832 |
| Eps Current Year | 27.574 |
| Eps Forward | 30.03392 |
| Eps Trailing Twelve Months | 27.26 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 530.7946 |
| Fifty Day Average Change | -15.334595 |
| Fifty Day Average Change Percent | -0.028889883 |
| Fifty Two Week Change Percent | 30.409325 |
| Fifty Two Week High | 609.35 |
| Fifty Two Week High Change | -93.88995 |
| Fifty Two Week High Change Percent | -0.15408215 |
| Fifty Two Week Low | 375.61 |
| Fifty Two Week Low Change | 139.85004 |
| Fifty Two Week Low Change Percent | 0.3723278 |
| Fifty Two Week Range | 375.61 - 609.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 929,626,200,000 |
| Float Shares | 39,212,815 |
| Forward Eps | 30.03392 |
| Forward P E | 17.162596 |
| Free Cashflow | 557,137,472 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,400 |
| Fullday Change | -12.45 |
| Fullday Change Percent | -2.35835 |
| Fullday Price | 515.46 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.8614 |
| Gross Profits | 2,717,299,968 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02003 |
| Held Percent Institutions | 0.99974 |
| Implied Shares Outstanding | 42,890,692 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,253,664,000 |
| Last Split Factor | 2:1 |
| Long Business Summary | United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland. |
| Long Name | United Therapeutics Corporation |
| Market | us_market |
| Market Cap | 22,108,436,480 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_36018 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 1,310,899,968 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 22,642,425,213 |
| Number Of Analyst Opinions | 12 |
| Open | 530.5 |
| Operating Cashflow | 1,685,200,000 |
| Operating Margins | 0.42231998 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.22 |
| Phone | 301 608 9292 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 515.46 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 527.91 |
| Price Eps Current Year | 18.693699 |
| Price Hint | 2 |
| Price To Book | 3.437065 |
| Price To Sales Trailing12 Months | 7.0085387 |
| Profit Margins | 0.41557 |
| Quick Ratio | 4.891 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.64286 |
| Region | US |
| Regular Market Change | -12.45 |
| Regular Market Change Percent | -2.35835 |
| Regular Market Day High | 530.5 |
| Regular Market Day Low | 513.72 |
| Regular Market Day Range | 513.72 - 530.5 |
| Regular Market Open | 530.5 |
| Regular Market Previous Close | 527.91 |
| Regular Market Price | 515.46 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 266,869 |
| Return On Assets | 0.11607 |
| Return On Equity | 0.19315 |
| Revenue Growth | -0.019 |
| Revenue Per Share | 72.852 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 42,890,692 |
| Shares Percent Shares Out | 0.0493 |
| Shares Short | 2,112,367 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,088,748 |
| Short Name | United Therapeutics Corporation |
| Short Percent Of Float | 0.0575 |
| Short Ratio | 4.22 |
| Source Interval | 15 |
| State | MD |
| Symbol | UTHR |
| Target High Price | 725.0 |
| Target Low Price | 515.0 |
| Target Mean Price | 664.3333 |
| Target Median Price | 685.0 |
| Total Cash | 2,662,299,904 |
| Total Cash Per Share | 62.072 |
| Total Debt | 0 |
| Total Revenue | 3,154,500,096 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 27.26 |
| Trailing P E | 18.909025 |
| Trailing Peg Ratio | 2.2213 |
| Triggerable | 1 |
| Two Hundred Day Average | 522.28906 |
| Two Hundred Day Average Change | -6.8290405 |
| Two Hundred Day Average Change Percent | -0.013075213 |
| Type Disp | Equity |
| Volume | 266,869 |
| Website | https://www.unither.com |
| Zip | 20,910 |